These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9042110)

  • 21. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
    Maas AI; Murray G; Henney H; Kassem N; Legrand V; Mangelus M; Muizelaar JP; Stocchetti N; Knoller N;
    Lancet Neurol; 2006 Jan; 5(1):38-45. PubMed ID: 16361021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.
    Knoller N; Levi L; Shoshan I; Reichenthal E; Razon N; Rappaport ZH; Biegon A
    Crit Care Med; 2002 Mar; 30(3):548-54. PubMed ID: 11990913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis.
    Bass R; Engelhard D; Trembovler V; Shohami E
    J Infect Dis; 1996 Mar; 173(3):735-8. PubMed ID: 8627042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO).
    Chen G; Shi JX; Hang CH; Xie W; Liu J; Liu X
    Neurosci Lett; 2007 Oct; 425(3):177-82. PubMed ID: 17825990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chloroquine exerts neuroprotection following traumatic brain injury via suppression of inflammation and neuronal autophagic death.
    Cui CM; Gao JL; Cui Y; Sun LQ; Wang YC; Wang KJ; Li R; Tian YX; Cui JZ
    Mol Med Rep; 2015 Aug; 12(2):2323-8. PubMed ID: 25872478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of memantine on lipid peroxidation following closed-head trauma in rats.
    Ozsüer H; Görgülü A; Kiriş T; Cobanoğlu S
    Neurosurg Rev; 2005 Apr; 28(2):143-7. PubMed ID: 15789251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury.
    Knoblach SM; Faden AI
    Exp Neurol; 1998 Sep; 153(1):143-51. PubMed ID: 9743576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
    Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
    J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. dl-3-n-butylphthalide reduces brain damage in mice with closed head injury.
    Chong Z; Feng Y
    Chin Med J (Engl); 2000 Jul; 113(7):613-6. PubMed ID: 11776030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats.
    Gurevich B; Artru AA; Lam AM; Mueller AL; Merkind V; Talmor D; Katchko L; Shapira Y
    J Neurosurg; 1998 Jun; 88(6):1066-74. PubMed ID: 9609302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat.
    Shohami E; Novikov M; Mechoulam R
    J Neurotrauma; 1993; 10(2):109-19. PubMed ID: 8411215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.
    Achiron A; Miron S; Lavie V; Margalit R; Biegon A
    J Neuroimmunol; 2000 Jan; 102(1):26-31. PubMed ID: 10626663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines.
    Panikashvili D; Shein NA; Mechoulam R; Trembovler V; Kohen R; Alexandrovich A; Shohami E
    Neurobiol Dis; 2006 May; 22(2):257-64. PubMed ID: 16364651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system.
    Striem S; Bar-Joseph A; Berkovitch Y; Biegon A
    Eur J Pharmacol; 1997 Nov; 338(3):205-13. PubMed ID: 9424014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective effect of carnosine and cyclosporine-A against inflammation, apoptosis, and oxidative brain damage after closed head injury in immature rats.
    Baky NA; Fadda L; Al-Rasheed NM; Al-Rasheed NM; Mohamed A; Yacoub H
    Toxicol Mech Methods; 2016 Jan; 26(1):1-10. PubMed ID: 26275125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Administration of monoclonal antibodies neutralizing the inflammatory mediators tumor necrosis factor alpha and interleukin -6 does not attenuate acute behavioral deficits following experimental traumatic brain injury in the rat.
    Marklund N; Keck C; Hoover R; Soltesz K; Millard M; LeBold D; Spangler Z; Banning A; Benson J; McIntosh TK
    Restor Neurol Neurosci; 2005; 23(1):31-42. PubMed ID: 15846030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B).
    Jüttler E; Potrovita I; Tarabin V; Prinz S; Dong-Si T; Fink G; Schwaninger M
    Neuropharmacology; 2004 Sep; 47(4):580-92. PubMed ID: 15380375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury.
    He J; Evans CO; Hoffman SW; Oyesiku NM; Stein DG
    Exp Neurol; 2004 Oct; 189(2):404-12. PubMed ID: 15380490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabinoids and brain injury: therapeutic implications.
    Mechoulam R; Panikashvili D; Shohami E
    Trends Mol Med; 2002 Feb; 8(2):58-61. PubMed ID: 11815270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors.
    Movsesyan VA; O'Leary DM; Fan L; Bao W; Mullins PG; Knoblach SM; Faden AI
    J Pharmacol Exp Ther; 2001 Jan; 296(1):41-7. PubMed ID: 11123360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.